Terrance P. Coyne - 11 Feb 2026 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role
EVP & CFO
Signature
/s/ Sean Weisberg, as Attorney-in-Fact for Terrance P. Coyne
Issuer symbol
RPRX
Transactions as of
11 Feb 2026
Net transactions value
$0
Form type
4
Filing time
13 Feb 2026, 16:03:15 UTC
Previous filing
04 Feb 2026
Next filing
25 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Coyne Terrance P. EVP & CFO C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK /s/ Sean Weisberg, as Attorney-in-Fact for Terrance P. Coyne 13 Feb 2026 0001814876

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPRX Class A Ordinary Shares Award $0 +26,626 +116% $0.000000 49,511 11 Feb 2026 TPC RP EPA1 LLC F1
holding RPRX Class A Ordinary Shares 164,580 11 Feb 2026 By TPC RP 2021, LLC
holding RPRX Class A Ordinary Shares 24,170 11 Feb 2026 By Spouse's IRA
holding RPRX Class A Ordinary Shares 23,270 11 Feb 2026 By IRA
holding RPRX Class A Ordinary Shares 1,500 11 Feb 2026 Direct
holding RPRX Class A Ordinary Shares 1,450 11 Feb 2026 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 6,448,180 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,807,277 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.